 COVID-19 , the disease caused by the coronavirus SARS-CoV-2, has inflicted considerable suffering on the human population. In this paper, we aim to significantly expand the resources available to biological and clinical researchers who are developing therapeutic targets for drug development and repositioning. Taking a genome-scale, systems-level view of virus-host interactions, we adapt and specialize network label propagation methods to prioritize drug targets based on their probability to inhibit host-pathogen interactions or their downstream signaling targets. In particular, our results suggest that we can predict human proteins that interact with SARS-CoV-2 proteins with high accuracy. Moreover, the top-ranking proteins scored by our methods are enriched in  biological processes that are relevant to the virus. We discuss cases where our methodology generates promising insights , including the potential role of HSPA5 in viral entry , the connection of HSPA5 and its interactors with anti-clotting drugs, and the role of tubulin proteins involved in ciliary assembly that are targeted by anti-mitotic drugs. Several drugs that we discuss are already undergoing clinical trials to test their efficacy against COVID-19. We make the prioritized list of human proteins and drug targets broadly available as a general resource for repositioning of existing and approved drugs  as anti-COVID-19 agents or for novel drug development .
Motivated by the critical need to identify new treatments for COVID-19 , we present a genome-scale, systems-level computational approach to prioritize drug targets based on their potential to regulate host-virus interactions or their downstream signaling targets. We adapt and specialize network label propagation methods to this end. We demonstrate that these techniques can predict human-SARS-CoV-2 protein interactors with high accuracy. The top-ranked proteins that we identify are enriched in host biological processes that are potentially coopted by the virus. We present cases where our methodology generates promising insights such as the potential role of HSPA5 in viral entry . We highlight the connection between endoplasmic reticulum stress, HSPA5 , and anti-clotting agents. We identify tubulin proteins involved in ciliary assembly that are targeted by anti-mitotic drugs. Drugs that we discuss are already undergoing clinical trials to test their efficacy against COVID-19. Our prioritized list of human proteins and drug targets is available as a general resource for biological and clinical researchers who are repositioning existing and approved drugs or developing novel therapeutics as anti-COVID-19 agents .
A
Motivated by the critical need to identify new treatments for
R
, the disease caused by the coronavirus SARS-CoV-2, has inflicted considerable suffering on the human population. In this paper, we aim to significantly expand the resources available to biological and clinical researchers who are developing therapeutic targets for drug development and repositioning. Taking
, we present
R
view of virus-host interactions, we adapt and specialize network label propagation methods
computational approach
R
probability to inhibit host-pathogen
potential to regulate host-virus
R
In particular, our results suggest that we can predict human proteins that interact with SARS-CoV-2 proteins with
We adapt and specialize network label propagation methods to this end. We demonstrate that these techniques can predict human-SARS-CoV-2 protein interactors with
R
Moreover, the top-ranking proteins scored by our methods
The top-ranked proteins that we identify
A
host
R
relevant to
potentially coopted by
R
discuss
present
R
, including
such as
R
, the connection of
. We highlight the connection between endoplasmic reticulum stress,
R
and its interactors with
, and
R
drugs, and the role of
agents. We identify
R
Several drugs
Drugs
R
We make the
Our
R
broadly
is
R
repositioning of
biological and clinical researchers who are repositioning
A
or developing novel therapeutics
D
or for novel drug development